The pursuit of optimal visual acuity requires a sophisticated approach to contact lens selection, particularly when dealing with the intersection of astigmatism and presbyopia. Biofinity, a cornerstone of CooperVision's silicone hydrogel portfolio, represents a technical milestone in ocular comfort and stability. For the UK consumer, navigating the trial process for Biofinity lenses—specifically the Toric Multifocal variant—necessitates an understanding of the precise prescription options and the material science that underpins the wearer's experience. The transition to these lenses is often managed through a trial phase, where the primary objective is to achieve a successful initial fit. Data indicates that when the specific fitting guide is utilised, the Biofinity toric multifocal achieves a 93% success rate on the first attempt. This high efficacy is attributed to the expansive range of prescription combinations, which exceed 200,000 options, ensuring that the unique ocular anatomy of each patient is addressed with precision.
The material composition of the Biofinity range is central to its appeal. By employing Aquaform Technology, these lenses ensure a high level of breathability and moisture retention. This is not merely a matter of comfort; the high oxygen permeability is critical for maintaining the health of the cornea, preventing hypoxia and ensuring that the eye remains hydrated throughout the wearing cycle. For users, this translates to a natural feel and the ability to engage in flexible wearing schedules, including suitability for overnight wear.
Technical Specifications of Biofinity Toric Multifocal Lenses
The Biofinity toric multifocal lens is engineered to address three simultaneous visual challenges: distance vision, near vision (presbyopia), and astigmatism. The complexity of this lens is reflected in its extensive parameter range.
The sphere power, which corrects basic nearsightedness or farsightedness, ranges from +10.00 to -10.00. For prescriptions between +6.00 and -6.00, the lenses are available in 0.50 steps, allowing for a granular approach to corrective power. The cylinder power, essential for correcting astigmatism, spans from -0.75 to -5.75, provided in 0.50 increments. The axis, which determines the orientation of the cylinder correction, ranges from 5 degrees to 180 degrees, moving in 5-degree steps.
Furthermore, the ADD powers, which provide the necessary boost for near-vision tasks, are available in +1.00, +1.50, +2.00, and +2.50. Each of these ADD powers is further categorised into "D" and "N" lens types, allowing the eye care professional to fine-tune the balance between distance and near visual acuity.
| Parameter | Range/Value | Increments |
|---|---|---|
| Sphere Power | +10.00 to -10.00 | 0.50 steps after +/-6.00D |
| Cylinder Power | -0.75 to -5.75 | 0.50 steps |
| Axis | 5 to 180 degrees | 5-degree steps |
| ADD Powers | +1.00, +1.50, +2.00, +2.50 | Available in D and N lenses |
Clinical Applications and Myopia Control in Paediatrics
The utility of Biofinity multifocal lenses extends beyond the correction of presbyopia into the realm of myopia control for children. The Bifocal Lenses In Nearsighted Kids (BLINK) study, sponsored by the National Eye Institute, has investigated the effects of soft multifocal contact lenses on the progression of myopia in children aged 7 to 11 years.
The study focused on subjects with a spherical component between -0.75 and -5.00 and astigmatism of less than 1.00 diopter (D). A critical requirement for participants was achieving 20/25 or better logMAR distance visual acuity using manifest refraction and +2.50-D add soft bifocal contact lenses.
The methodology involved randomly assigning children to one of three groups:
- Biofinity single-vision lenses.
- Biofinity Multifocal "D" lenses with a +1.50-D add power.
- Biofinity Multifocal "D" lenses with a +2.50-D add power.
The selection of Biofinity Multifocal lenses for this study was predicated on their ability to provide myopic defocus at 20, 30, and 40 degrees nasally and temporally while the wearer focuses on a distance. Crucially, no myopic blur was detected when looking at near objects, making them an ideal candidate for investigating the potential mechanisms of myopia control.
The baseline characteristics of the BLINK study cohort included 294 enrolled subjects, 60.2% of whom were female and 68% of whom were white. The mean age of participants was 10.3 years, with 39.8% of the group being under 10 years old. The mean spherical equivalent refractive error, as measured by cycloplegic autorefraction, was -2.39 D.
The Trial Process and Professional Fitting
For consumers seeking a Biofinity trial, the fitting process is a critical juncture. The stability and comfort reported by patients are the result of rigorous fitting protocols. Professionals may utilise the toric and multifocal fitting calculator within the OptiExpert app, available on the App Store and Google Play, to streamline the selection of the correct lens parameters.
In clinical trial settings, such as the BLINK study, the fitting process is exhaustive. Subjects undergo cycloplegic autorefraction using the Grand Seiko WAM-5500 Binocular Autorefractor/Keratometer. This process involves the application of 0.5% proparacaine or tetracaine, followed by two drops of 1.0% tropicamide. Measurements are taken 25 minutes after the second drop to ensure complete relaxation of the accommodation.
The evaluation of fit is binary; if a subject exhibits an unacceptable fit—defined as limbal exposure, excessive movement, or no movement—they are deemed ineligible for the study. In instances where a poor fit occurs during subsequent visits, Proclear or Proclear Multifocal "D" lenses are used as the primary backup due to their similar optical profile.
Visual acuity during trials is measured using Bailey-Lovie logMAR high-contrast charts and low-contrast visual acuity charts, calibrated to 75 to 120 cd/m2. This ensures that the trial is measured against a standardised baseline of lighting and contrast.
Comparative Analysis of Contact Lens Trial Options
While Biofinity offers a premium experience, consumers often compare these options with other silicone hydrogel alternatives. A notable comparison can be seen in the pricing and features of the everclear ELITE lens, which is often available as a complimentary online trial.
The everclear ELITE lens features an ultra-flexible silicone hydrogel material designed for hydration and a secure fit, coupled with a UV filter to protect against harmful rays. In terms of cost-efficiency, the everclear ELITE is positioned as a value-driven alternative.
The following table compares the costs associated with various lens options as of June 2025:
| Lens | Per Pack | Per Month | Per Year |
|---|---|---|---|
| Dailies Total 1 | £23.49 | £46.98 | £563.76 |
| Dailies Aquacomfort Plus | £16.49 | £32.98 | £395.76 |
| Precision 1 | £22.99 | £45.98 | £551.76 |
| everclear ELITE | £14.99 | £29.98 | £359.76 |
It is important to note that while complimentary trial packs are available for everclear ELITE, they cannot be transferred to other products. Furthermore, a delivery fee of £3.98 applies.
Material Science and User Comfort
The success of the Biofinity trial is heavily reliant on the Aquaform Technology integrated into the lenses. This technology is a defining characteristic of CooperVision's silicone hydrogel range, focusing on two primary vectors: breathability and moisture content.
The impact of this technology on the user is multi-faceted:
- Oxygen Permeability: The high permeability allows oxygen to reach the cornea effectively, which is essential for ocular health and prevents the "stuffy" feeling associated with lower-quality lenses.
- Hydration: The higher moisture content ensures that the lenses remain lubricated, reducing the friction between the lens and the eyelid.
- Stability: For those using the Toric variant, the lens is designed to resist rotation on the eye, ensuring that the astigmatism correction remains aligned with the cornea.
- Flexibility: The material allows for flexible wearing times, making the lenses suitable for those who prefer not to remove their lenses every single night, provided they have professional approval for overnight wear.
Logistical Requirements for Trial Participants
In structured clinical environments, the provision of materials during a trial is comprehensive. Participants in the BLINK study, for instance, received the following without cost:
- Free contact lenses.
- Contact lens solutions.
- Contact lens cases.
The management of the prescription during the trial is also dynamic. New lens powers are provided if overrefraction exhibits myopia progression of more than 0.50 D, or if the examiner determines it is clinically necessary.
The use of solutions is also standardised; participants initially received Biotrue (Bausch + Lomb) solution. The wearing pattern encouraged was maximum daily use for comfort, although no extended wear was permitted in the context of the BLINK study, and patients were encouraged to use glasses whenever they wished.
Analysis of Visual Outcomes and Patient Feedback
The efficacy of the Biofinity toric multifocal trial is evidenced by qualitative and quantitative data. Patient feedback consistently highlights "incredible comfort" and "stability," particularly regarding the toric aspect of the lens.
The impact on visual acuity is split between two domains:
- Distance Vision: The lens maintains the stability required to provide clear distance vision, which is a primary requirement for the toric element.
- Near Vision: The multifocal ADD powers provide the necessary assistance for reading and close-up tasks, with patient feedback indicating high satisfaction with the first trial pair.
The success rate of 93% for initial fitting suggests that thecombination of the fitting guide and the vast array of prescription options removes most of the trial-and-error usually associated with multifocal toric lenses. This efficiency reduces the number of follow-up appointments required and accelerates the patient's transition to a permanent corrective solution.
Conclusion
The Biofinity trial ecosystem represents a convergence of high-precision manufacturing and clinical rigor. By offering over 200,000 prescription combinations, CooperVision has effectively minimised the risks associated with fitting complex toric multifocal lenses. The integration of Aquaform Technology ensures that the physical experience of wearing the lens—marked by high oxygen permeability and moisture—matches the optical performance. Whether used for the correction of presbyopia in adults or as a tool for myopia control in children via the BLINK study, the Biofinity range demonstrates a consistent ability to provide stability and comfort.
When compared to other market options like the everclear ELITE, Biofinity occupies a space of high-specification, tailor-made correction. While value-driven trials are available for daily disposables, the Biofinity trial is an exercise in professional customisation. The clinical evidence suggests that the use of specific fitting tools, such as the OptiExpert app and standardised cycloplegic autorefraction, is paramount to achieving the reported 93% initial success rate. Ultimately, the Biofinity trial process is not merely about testing a product, but about the precise mapping of a lens to the unique physiological needs of the human eye.